Almitrine Bismesylate + Raubasine
Pregnancy. Long term treatment may result in numbness, prickling or formication effects in the lower limbs which may, in rare cases, lead to treatment withdrawal.
Cerebrovascular insufficiency, Functional rehabilitation after cerebrovascular accidents, Auditory, Vestibular and visual disorders of ischaemic aetiology, Stroke
Concurrent usage with MAOIs.
N/A
Mild GI disorders, sleep disturbances, palpitations, anxiety, dizziness. Rarely, wt loss, peripheral neuropathy with abnormal sensations in the lower limbs.
Almitrine and raubasine work together to increase the amount of oxygen brought to the brain and neurosensory tissue, by increasing the oxygen content of arterial blood.
Not to be used concurrently with other almitrine-containing preparations. Potentially Fatal: MAOIs.
N/A
Adult: PO Auditory, vestibular and visual disorders of ischaemic aetiology; Cerebrovascular insufficiency; Functional rehabilitation after cerebrovascular accidents Per tab contains almitrine 30 mg and raubasine 10 mg: 1 tab twice daily.
N/A
N/A
N/A
The information provided herein are for informational purposes only and not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please note that this information should not be treated as a replacement for physical medical consultation or advice. Great effort has been placed to provide accurate and comprehensive data. However, Medicart along with its authors and editors make no representations or warranties and specifically disclaim all liability for any medical information provided on the site. The absence of any information and/or warning to any drug shall not be considered and assumed as an implied assurance of the Company.